{
  "content": "Conclusions: Amiodarone treatment of AF is associated with increased mortality in patients without structural heart disease and therefore should be avoided or only used as a second-line therapy, when other AF therapies fail. Adherence to guideline recommendations in the management of AF patients impacts clinical outcome.\nKeywords: amiodarone; atrial fibrillation; mortality; outcome.\nPubMed Disclaimer\nComment in",
  "source": "https://pubmed.ncbi.nlm.nih.gov/26412606/",
  "chunk_id": "da417cf6-be6a-4cfe-a52b-c127fa063d41",
  "similarity_score": 0.31442344188690186,
  "query": "atrial fibrillation mortality outcomes cardiovascular events stroke prevention amiodarone beta-blockers hazard ratio",
  "rank": 33,
  "title": "Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease",
  "authors": "Dingxin Qin, George Leef, Mian Bilal Alam, Rohit Rattan, Mohamad Bilal Munir, Divyang Patel, Furqan Khattak, Evan Adelstein, Sandeep K Jain, Samir Saba",
  "year": "2015",
  "journal": "Cardiology Journal",
  "reference": "Qin, D., Leef, G., Alam, M. B., Rattan, R., Munir, M. B., Patel, D., Khattak, F., Adelstein, E., Jain, S. K., & Saba, S. (2015). Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease. Cardiology Journal, 22(6), 622-629. https://doi.org/10.5603/CJ.a2015.0055",
  "doi": "10.5603/CJ.a2015.0055",
  "chunk_index": 8,
  "total_chunks": 20,
  "retrieved_at": "2025-07-24T21:57:59.084687"
}